Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Aurora Cannabis Inc.NASDAQ: ACB

Financing Cash Flow · Q4 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q4 FY2026 financing cash flow of CA$13.48M rose 55.0% year over year, behind the +1152.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 977.8% from the prior quarter.

Context

  • Financing cash flow amounted to 3.0% of revenue in FY2026, up 3.0 pp from a year earlier.
  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +55.0% toward the trailing-twelve-month pace of +1152.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$13.48M+977.8% QoQ
Last fiscal yearMar 2026
CA$9.79M+8536.4% YoY
LTMMar 2026
CA$9.8M+1152.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.0%——
1 year+8536.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CAD · from the cash flow

Latest · FY2026
9.79M CAD
Year-over-year change
+8536.4%
4-year CAGR
-49.3%

Financing Cash Flow vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1152.7% is the highest of 10, against a peer median of -23.0%.
  • Financing cash flow amounts to 3.2% of revenue for ACB, versus a peer median of 4.9%.
ACB Competitors
Financing Cash Flow for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$366.4M CAD+146.5%—117.3%
BIOABioAge Labs, Inc.LTM Mar 2026$136.68M USD-35.4%+66.2%1325.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.19M USD-29.8%—623.8%
EDITEditas Medicine, Inc.LTM Mar 2026$41.91M USD-23.0%+215.9%108.3%
LFMDLifeMD, Inc.LTM Mar 2026$13.29M USD+242.2%+193.9%6.1%
ACBAurora Cannabis Inc.LTM Mar 2026CA$9.8M CAD+1152.7%—3.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.09M USD——3.8%
OGIOrganigram Global Inc.LTM Mar 2026CA$1.87M CAD-101.7%—0.7%
HITIHigh Tide Inc.LTM Apr 2026CA$608.92K CAD+104.3%-76.3%0.1%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$210K USD+100.2%—0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$85K USD-100.6%-75.5%0.2%
Peer median (excluding ACB) —-23.0%+66.2%4.9%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(57.08M)15.76M(58.77M)
Depreciation & Amortization93.66M43.57M32.78M22.55M14.23M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55.14K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.54M)10.21M(9.24M)
Accounts Receivables18.34M5.53M(4.5M)5.24M(8.17M)
Inventory21.07M49.03M3.87M(15.05M)65.93M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.06M)
Other Working Capital6.48M(71.61M)790K5.11M(58.93M)
Other Non-Cash Items1.45B190.11M(39.71M)(40.85M)40.18M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.55M)
Capital Expenditures(32.21M)(12.13M)(16.83M)(18.86M)(22.6M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments0000(52.35M)
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K14.02M(956K)235.61K
Investing Cash Flow(36.17M)(27.29M)(3.36M)(14.33M)(73.62M)
Debt Repayment(170.83M)—(85.37M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.92M820K9.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(475K)(131K)(154.4K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.79M
Effect of Forex Changes15.01M15.54M297K264K10.56M
Net Change in Cash16.35M(140.01M)(119.5M)1.83M(66.81M)
Free Cash Flow(142.48M)(127.95M)(85.34M)(2.85M)(36.15M)

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.